Zoetis Stock Rises 0.5% on Raised Earnings Outlook and $1.85B Debt Offering Despite 27.14% Drop in Daily Trading Volume

Zoetis Inc. (ZTS) rose 0.50% on August 12, 2025, with a trading volume of $330 million, marking a 27.14% decline from the previous day’s activity. The stock’s performance followed key developments in its financial strategy and earnings outlook.

The company priced a $1.85 billion debt offering of senior notes, signaling capital allocation priorities. Zoetis also raised its full-year 2025 earnings guidance after reporting stronger-than-expected Q2 results, driven by robust demand for pet health products. Analysts adjusted price targets, with Piper Sandler maintaining an Overweight rating and Leerink Partners sticking to Market Perform despite lowering its target to $153. Morgan Stanley reduced its price target to $221 but kept an Overweight stance, reflecting ongoing confidence in the stock’s long-term potential.

Recent earnings highlights include a $2.46 billion revenue beat against estimates of $2.41 billion and adjusted EPS of $1.76, surpassing the FactSet consensus of $1.62. These results underscore Zoetis’ resilience in its core markets, particularly in companion animal healthcare, which offset challenges in other segments like the Librela product line.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a $2,300 profit from 2022 to the present. However, the approach faced a maximum drawdown of -15.7% in early 2023, highlighting the volatility inherent in short-term trading strategies.